StockNews.com Initiates Coverage on Titan Pharmaceuticals (NASDAQ:TTNP)

Research analysts at StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Down 2.4 %

Shares of TTNP opened at $3.70 on Friday. The company has a market capitalization of $3.38 million, a PE ratio of -0.71 and a beta of 1.27. Titan Pharmaceuticals has a 52-week low of $3.03 and a 52-week high of $14.80. The company has a 50-day simple moving average of $3.72 and a 200-day simple moving average of $3.76.

Titan Pharmaceuticals (NASDAQ:TTNP) last posted its earnings results on Thursday, March 20th. The specialty pharmaceutical company reported ($0.85) EPS for the quarter.

Titan Pharmaceuticals Company Profile

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.